Jiangsu, China

Kangping Guo

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Jiangsu, CN (2018)
  • Suzhou, CN (2023)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kangping Guo: Innovator in Tumor Treatment

Introduction

Kangping Guo is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of methods for treating tumors. With a total of 4 patents to his name, Guo's work is paving the way for innovative cancer therapies.

Latest Patents

One of Guo's latest patents is a method for treating tumors using anti-CTLA4 single-domain antibodies. This patent discloses a method that utilizes a CTLA4-binding protein, which specifically binds to CTLA4 without competing with its ligand. This innovative approach effectively inhibits tumor growth. Another significant patent involves the creation of dimers formed by two polypeptide chains, each comprising an antibody Fc subunit. This dimer includes two or more immunoglobulin single variable domains (ISVDs), with at least one ISVD specific for PD-L1 and another for CTLA4.

Career Highlights

Kangping Guo has worked with prominent companies in the biopharmaceutical sector, including Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Suzhou Alphamab Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative treatments for cancer.

Collaborations

Guo has collaborated with notable colleagues in his field, including Ting Xu and Pilin Wang. These partnerships have likely enhanced his research and development efforts, leading to groundbreaking advancements in tumor treatment.

Conclusion

Kangping Guo is a distinguished inventor whose work in tumor treatment is making a significant impact in the biopharmaceutical industry. His innovative patents and collaborations highlight his commitment to advancing cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…